FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898192701> ?p ?o ?g. }

• W2898192701 endingPage "925.e1" @default.
• W2898192701 startingPage "918" @default.
• W2898192701 abstract "Background & AimsGuidelines recommend withholding clopidogrel 7 days before polypectomy to decrease bleeding risk, but these were written based on limited evidence. We investigated whether uninterrupted clopidogrel therapy increases the risk of delayed postpolypectomy bleeding in patients undergoing colonoscopy.MethodsWe identified patients receiving clopidogrel for cardiovascular disease undergoing elective colonoscopies in Hong Kong from February 28, 2012 through April 11, 2018. Eligible patients were instructed to stop taking clopidogrel 7 days before colonoscopy. Then, they were randomly assigned to groups given clopidogrel (75 mg) or placebo daily until the morning of colonoscopy. All patients resumed their usual prescriptions of clopidogrel after colonoscopy. The primary end point was delayed postpolypectomy bleeding that required hospitalization or intervention up to 30 days after colonoscopy. Secondary end points were immediate postpolypectomy bleeding and serious cardio-thrombotic events for as long as 6 months after colonoscopy, according to Antithrombotic Trialists’ criteria. All events were adjudicated by an independent masked committee.ResultsIn total, 387 patients underwent colonoscopy and 216 required polypectomies (106 patients in the clopidogrel group and 110 patients in the placebo group). The cumulative incidence of delayed postpolypectomy bleeding was 3.8% (95% confidence interval 1.4–9.7) in the clopidogrel group and 3.6% (95% confidence interval 1.4–9.4) in the placebo group (P = .945 by log-rank test). There were no significant differences in immediate postpolypectomy bleeding (8.5% vs 5.5%; P = .380) and cardio-thrombotic events (1.5% vs 2%; P = .713).ConclusionsIn a randomized controlled trial of clopidogrel users undergoing colonoscopy, a slightly larger proportion of patients continuing clopidogrel developed delayed and immediate postpolypectomy bleeding, although this difference was not statistically significant. ClinicalTrials.gov, number NCT01806090. Guidelines recommend withholding clopidogrel 7 days before polypectomy to decrease bleeding risk, but these were written based on limited evidence. We investigated whether uninterrupted clopidogrel therapy increases the risk of delayed postpolypectomy bleeding in patients undergoing colonoscopy. We identified patients receiving clopidogrel for cardiovascular disease undergoing elective colonoscopies in Hong Kong from February 28, 2012 through April 11, 2018. Eligible patients were instructed to stop taking clopidogrel 7 days before colonoscopy. Then, they were randomly assigned to groups given clopidogrel (75 mg) or placebo daily until the morning of colonoscopy. All patients resumed their usual prescriptions of clopidogrel after colonoscopy. The primary end point was delayed postpolypectomy bleeding that required hospitalization or intervention up to 30 days after colonoscopy. Secondary end points were immediate postpolypectomy bleeding and serious cardio-thrombotic events for as long as 6 months after colonoscopy, according to Antithrombotic Trialists’ criteria. All events were adjudicated by an independent masked committee. In total, 387 patients underwent colonoscopy and 216 required polypectomies (106 patients in the clopidogrel group and 110 patients in the placebo group). The cumulative incidence of delayed postpolypectomy bleeding was 3.8% (95% confidence interval 1.4–9.7) in the clopidogrel group and 3.6% (95% confidence interval 1.4–9.4) in the placebo group (P = .945 by log-rank test). There were no significant differences in immediate postpolypectomy bleeding (8.5% vs 5.5%; P = .380) and cardio-thrombotic events (1.5% vs 2%; P = .713). In a randomized controlled trial of clopidogrel users undergoing colonoscopy, a slightly larger proportion of patients continuing clopidogrel developed delayed and immediate postpolypectomy bleeding, although this difference was not statistically significant. ClinicalTrials.gov, number NCT01806090." @default.
• W2898192701 created "2018-11-02" @default.
• W2898192701 creator A5000349522 @default.
• W2898192701 creator A5000503303 @default.
• W2898192701 creator A5001862025 @default.
• W2898192701 creator A5007692779 @default.
• W2898192701 creator A5026611066 @default.
• W2898192701 creator A5043291688 @default.
• W2898192701 creator A5043503140 @default.
• W2898192701 creator A5052217593 @default.
• W2898192701 creator A5057276676 @default.
• W2898192701 creator A5064715130 @default.
• W2898192701 creator A5085313387 @default.
• W2898192701 creator A5087329414 @default.
• W2898192701 creator A5090358214 @default.
• W2898192701 date "2019-03-01" @default.
• W2898192701 modified "2023-10-17" @default.
• W2898192701 title "Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial" @default.
• W2898192701 cites W1970262067 @default.
• W2898192701 cites W1974373698 @default.
• W2898192701 cites W1982188862 @default.
• W2898192701 cites W2012116426 @default.
• W2898192701 cites W2023222759 @default.
• W2898192701 cites W2035629916 @default.
• W2898192701 cites W2045390935 @default.
• W2898192701 cites W2065132155 @default.
• W2898192701 cites W2108514030 @default.
• W2898192701 cites W2146743728 @default.
• W2898192701 cites W2159605533 @default.
• W2898192701 cites W2161254333 @default.
• W2898192701 cites W2201074817 @default.
• W2898192701 cites W2305958372 @default.
• W2898192701 cites W2336962966 @default.
• W2898192701 cites W2520786713 @default.
• W2898192701 cites W2523791325 @default.
• W2898192701 cites W2588184175 @default.
• W2898192701 cites W2789486198 @default.
• W2898192701 doi "https://doi.org/10.1053/j.gastro.2018.10.036" @default.
• W2898192701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30518511" @default.
• W2898192701 hasPublicationYear "2019" @default.
• W2898192701 type Work @default.
• W2898192701 sameAs 2898192701 @default.
• W2898192701 citedByCount "34" @default.
• W2898192701 countsByYear W28981927012019 @default.
• W2898192701 countsByYear W28981927012020 @default.
• W2898192701 countsByYear W28981927012021 @default.
• W2898192701 countsByYear W28981927012022 @default.
• W2898192701 countsByYear W28981927012023 @default.
• W2898192701 crossrefType "journal-article" @default.
• W2898192701 hasAuthorship W2898192701A5000349522 @default.
• W2898192701 hasAuthorship W2898192701A5000503303 @default.
• W2898192701 hasAuthorship W2898192701A5001862025 @default.
• W2898192701 hasAuthorship W2898192701A5007692779 @default.
• W2898192701 hasAuthorship W2898192701A5026611066 @default.
• W2898192701 hasAuthorship W2898192701A5043291688 @default.
• W2898192701 hasAuthorship W2898192701A5043503140 @default.
• W2898192701 hasAuthorship W2898192701A5052217593 @default.
• W2898192701 hasAuthorship W2898192701A5057276676 @default.
• W2898192701 hasAuthorship W2898192701A5064715130 @default.
• W2898192701 hasAuthorship W2898192701A5085313387 @default.
• W2898192701 hasAuthorship W2898192701A5087329414 @default.
• W2898192701 hasAuthorship W2898192701A5090358214 @default.
• W2898192701 hasConcept C121608353 @default.
• W2898192701 hasConcept C126322002 @default.
• W2898192701 hasConcept C141071460 @default.
• W2898192701 hasConcept C142724271 @default.
• W2898192701 hasConcept C168563851 @default.
• W2898192701 hasConcept C203092338 @default.
• W2898192701 hasConcept C204787440 @default.
• W2898192701 hasConcept C27081682 @default.
• W2898192701 hasConcept C2777628954 @default.
• W2898192701 hasConcept C2777849778 @default.
• W2898192701 hasConcept C2778435480 @default.
• W2898192701 hasConcept C2780581329 @default.
• W2898192701 hasConcept C44249647 @default.
• W2898192701 hasConcept C526805850 @default.
• W2898192701 hasConcept C71924100 @default.
• W2898192701 hasConceptScore W2898192701C121608353 @default.
• W2898192701 hasConceptScore W2898192701C126322002 @default.
• W2898192701 hasConceptScore W2898192701C141071460 @default.
• W2898192701 hasConceptScore W2898192701C142724271 @default.
• W2898192701 hasConceptScore W2898192701C168563851 @default.
• W2898192701 hasConceptScore W2898192701C203092338 @default.
• W2898192701 hasConceptScore W2898192701C204787440 @default.
• W2898192701 hasConceptScore W2898192701C27081682 @default.
• W2898192701 hasConceptScore W2898192701C2777628954 @default.
• W2898192701 hasConceptScore W2898192701C2777849778 @default.
• W2898192701 hasConceptScore W2898192701C2778435480 @default.
• W2898192701 hasConceptScore W2898192701C2780581329 @default.
• W2898192701 hasConceptScore W2898192701C44249647 @default.
• W2898192701 hasConceptScore W2898192701C526805850 @default.
• W2898192701 hasConceptScore W2898192701C71924100 @default.
• W2898192701 hasFunder F4320322942 @default.
• W2898192701 hasIssue "4" @default.
• W2898192701 hasLocation W28981927011 @default.
• W2898192701 hasLocation W28981927012 @default.
• W2898192701 hasOpenAccess W2898192701 @default.
• W2898192701 hasPrimaryLocation W28981927011 @default.

• next